The DEA's cannabis rescheduling hearing is entering its final stretch, yet the public still has very little visibility into what has transpired inside the hearing room. Until the proceedings conclude and the transcripts are released, nearly everything being discussed outside the hearing remains a mixture of public filings, participant statements, and speculation.
One theory has continued to surface: what if participants opposing rescheduling walked into the hearing expecting one debate, only to discover they were having another?
Whether that's true is impossible to know today. The transcripts will ultimately tell that story.
But if it were true, it would raise an interesting question.
Imagine defending a lawsuit believing the central issue will be whether your client is liable. As the proceedings unfold, however, it becomes increasingly clear that liability is likely to be established. Experienced attorneys don't continue arguing as though nothing has changed. They adapt. Their focus shifts toward limiting damages, preserving favorable terms, and shaping the final judgment as much as possible.
The objective hasn't disappeared. The strategy has evolved.
If a similar dynamic emerged during the DEA hearing, one would expect at least some of the discussion to shift toward the practical consequences of rescheduling rather than the scheduling decision alone.
That could mean increased attention to the policies that would remain important regardless of where cannabis ultimately lands under the Controlled Substances Act.
Workplace drug testing is one obvious example. Employers, particularly those in safety-sensitive industries, will continue to require clear guidance regardless of cannabis's scheduling status.
Roadway safety is another. Few people dispute the importance of preventing impaired driving. The challenge has never been deciding whether impairment should be addressed, but rather determining how to measure it accurately. Cannabis presents a unique challenge because evidence of prior use does not necessarily indicate current impairment.
Federal funding for prevention, education, and public health initiatives could represent another logical area of focus. If the broader scheduling debate appeared to be moving in a different direction, preserving those programs would become an increasingly important objective.
This isn't an argument that anyone was unprepared, nor is it a claim about what has occurred behind closed doors. It is simply an observation about how high-stakes policy disputes often evolve. When one outcome begins to appear increasingly likely, experienced advocates frequently shift their attention from preventing that outcome to shaping its consequences.
Interestingly, Congress appears to be moving along a parallel path. Lawmakers have renewed efforts to fund research into objective cannabis impairment standards for driving and other safety-sensitive situations. While those efforts are separate from the DEA's rescheduling proceeding, they reflect the same practical reality: if federal cannabis policy is changing, regulators will eventually need scientifically reliable and legally defensible ways to distinguish actual impairment from prior use.
The public conversation has largely centered on a single question: Will cannabis be moved to Schedule III?
The hearing transcripts may ultimately reveal that another question became just as important.
If rescheduling increasingly appeared to be the likely destination, what policies, safeguards, and public safety measures did participants believe should accompany it?
When the transcripts are finally released, the most revealing portions may not be the arguments for or against rescheduling itself. They may be the moments where the conversation shifted from debating whether change should occur to defining how that change should be managed.